STOCK TITAN

Twist Bioscience (TWST) Form 144: 233 Shares from Restricted Vesting to Be Sold

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Twist Bioscience (TWST) Form 144 shows a proposed sale of 233 common shares valued at $6,421.46 to be executed on 09/22/2025 through Fidelity Brokerage Services on NASDAQ. The shares were acquired on 09/19/2025 via restricted stock vesting and were paid as compensation.

The filer, identified in the notice as Dennis H. Cho, also reported five prior open-market sales in the past three months totaling 1,794 shares for aggregate gross proceeds of $49,627.58 (sales between 07/02/2025 and 09/15/2025). The filing includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Positive

  • Clear disclosure of acquisition method: restricted stock vesting and payment as compensation
  • Broker and execution details provided (Fidelity Brokerage Services; NASDAQ execution)
  • Prior sales fully reported for the past three months with dates and gross proceeds

Negative

  • Insider has sold 1,794 shares in the past three months for $49,627.58, which may be noticed by investors
  • Proposed sale increases immediate share supply by 233 shares (market value $6,421.46) on 09/22/2025

Insights

TL;DR: Routine insider sale of vested restricted stock; size is small relative to typical public float, appears compensatory.

The filing documents a proposed sale of 233 shares valued at $6,421.46 arising from restricted stock vesting. Recent activity shows 1,794 shares sold for $49,627.58 over three months. From an equity-analyst perspective, these transactions are consistent with executive compensation monetization rather than a company-level financing or change in operating fundamentals. There is no financial performance data or forward guidance in this filing to assess operational impact. The disclosed amounts are quantitatively modest and do not, by themselves, indicate a material change to share supply or investor valuation.

TL;DR: Form 144 appears properly completed for a Rule 144 sale of recently vested shares; disclosure meets routine compliance expectations.

This notice identifies the acquisition method (restricted stock vesting), payment as compensation, broker details (Fidelity Brokerage Services), and planned sale date. It also lists prior sales by the same person in the preceding three months with amounts and gross proceeds, aligning with required aggregation disclosure. The signature/representation language regarding material non-public information is present. The filing does not show any inconsistencies or missing mandatory fields based on the content provided.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TWST Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 233 common shares valued at $6,421.46 to be sold on 09/22/2025 through Fidelity on NASDAQ.

How were the 233 shares acquired according to the filing?

The shares were acquired on 09/19/2025 via restricted stock vesting and the payment was for compensation.

How many shares did the insider sell in the prior three months?

The filing reports five sales totaling 1,794 shares for aggregate gross proceeds of $49,627.58 between 07/02/2025 and 09/15/2025.

Who is the seller named in the Form 144?

The seller named in the filing is Dennis H. Cho, with prior sales listed at a San Francisco address.

Does the filing indicate any undisclosed material information about Twist Bioscience?

By signing, the filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.
Twist Bioscience

NASDAQ:TWST

View TWST Stock Overview

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.65B
60.41M
Diagnostics & Research
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO